New hope for rare liver infection: drug trial underway
NCT ID NCT06649266
First seen Feb 03, 2026 · Last updated Apr 25, 2026 · Updated 13 times
Summary
This study tests a new drug called RBD1016 in 14 adults with chronic hepatitis D, a serious liver infection. The goal is to see if the drug can lower the amount of virus in the blood and check for any side effects. Participants receive either RBD1016 or a placebo and visit the clinic every 4-6 weeks for about 60 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Infektionskliniken, Danderyds sjukhus
Stockholm, 18288, Sweden
-
Medicinsk enhet för Infektionssjukdomar, Karolinska Universitetssjukhuset Huddinge
Stockholm, 14186, Sweden
Conditions
Explore the condition pages connected to this study.